Changes

Jump to navigation Jump to search

Histogen

732 bytes removed, 12:38, 9 February 2020
m
no edit summary
On October 2012 Histogen announced preliminary data from a combined Phase 1/2 clinical trial. In this trial, patients aged 40-59 showed a mean increase of 39 percent in so-called terminal hair, as opposed to fine hair called vellus hair. Hair regrowth took place across all regions of the scalp.<ref name="hairgrowth"/>
 
== Gail K. Naughton ==
Naughton was president and COO of [[Advanced Tissue Sciences]], which produced a living skin product call [[Dermagraft]] used to help healing of diabetic foot ulcers. Dermagraft is now being made in San Diego by a subsidiary of [[Shire]], a medical company based in Dublin, Ireland.
 
Naughton founded Histogen in 2007, when she was dean of San Diego State University's College of Business Administration. Naughton, who had been dean since 2002, left in 2010 to focus on Histogen.
<ref>{{REFweb
|last=
|first=
|date=2012-09-05
|title=U.S. Patent issued for Histogen's Novel Cell Growth Process
|url=http://www.histogen.com/aboutus/news_events.htm#37
|publisher=Histogen
|accessdate=2012-11-16
}}</ref>
{{REF}}
administrator, administrators, Bureaucrats, Interface administrators, Administrators
22,197
edits

Navigation menu